^
Association details:
| Biomarker: | BRCA2 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | AiTan (rivoceranib) (VEGFR-2 inhibitor) + AiRuiYi (fluzoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis
Published date:
09/29/2023
Excerpt:
Patients with gBRCAmut had higher ORR and longer median progression-free survival (PFS) than those with gBRCAwt, both in OC (ORR, 62.5% [5/8] vs 40.9% [9/22]; PFS, 9.4 vs 6.7 months) and TNBC (ORR, 66.7% [2/3] vs 15.8% [3/19]; PFS, 5.6 vs 2.8 months)….In summary, the combination of fuzuloparib and apatinib showed hematologic DLTs and acceptable safety in patients with recurrent OC and TNBC.
DOI:
https://doi.org/10.1186/s12916-023-03046-8
Trial ID:
